Belluscura Regulatory News (BELL)

Belluscura plc

("Belluscura" or the "Company" or "Group")

 Senior Management Appointment

LONDON, U.K. AND PLANO, TX, U.S. (5 April 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Jim Clement has joined the Company as Head of Commercial Strategy.

Jim has over 30 years' experience in the durable medical equipment industry, including previously holding the title of General Manager of a portable oxygen concentrator company. Over his extensive career, Jim has held leadership positions in all areas of medical device manufacturing, particularly focused on Commercial Operations and Global Product Development of oxygen therapy devices. 

Robert Rauker, Chief Executive Officer, Belluscura plc, commented: "We are very excited to have Jim join our team. His extensive knowledge of the industry will be a valuable asset to the Company."

Jim Clement commented: "I'm looking forward to working with the Belluscura Team as we take their revolutionary technology through the next phase of growth and focus on patient care."

For further information please contact:

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.